Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

Shares in US pharma giant Merck & Co (NYSE: MRK) were nearly 2% higher in early trading Monday.

Merck, which is evaluating the safety and efficacy of enlicitide for the treatment of adults with hyperlipidemia on lipid-lowering therapies, including at least a statin, said the Phase 3 studies met ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...

A growing body of evidence is shifting expert opinion toward supporting MS treatment during pregnancy, emphasizing ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one of the most prestigious biopharmaceutical partnering events in APAC. Hosted annually by bioSeedin, BIOS ...

VeriSilicon (688521.SH) today announced that its ultra-low energy and high-performance Neural Network Processing Unit (NPU) IP now supports on-device inference of large language models (LLMs) with AI ...

Mergers and Acquisitions (M&A) have picked up significant pace in 2025 in the pharma/biotech sector after a passive run in 2024.The recent spree of acquisitions signifies a focus on portfolio ...